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Abstract
Pandemic influenza A virus (IAV) remains a significant threat to global health. Preparedness
relies primarily upon a single class of neuraminidase (NA) targeted antivirals, against which
resistance is steadily growing. The M2 proton channel is an alternative clinically proven anti-
viral target, yet a near-ubiquitous S31N polymorphism in M2 evokes resistance to licensed
adamantane drugs. Hence, inhibitors capable of targeting N31 containing M2 (M2-N31) are
highly desirable. Rational in silico design and in vitro screens delineated compounds favour-
ing either lumenal or peripheral M2 binding, yielding effective M2-N31 inhibitors in both
cases. Hits included adamantanes as well as novel compounds, with some showing low
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micromolar potency versus pandemic “swine” H1N1 influenza (Eng195) in culture. Interest-
ingly, a published adamantane-based M2-N31 inhibitor rapidly selected a resistant V27A
polymorphism (M2-A27/N31), whereas this was not the case for non-adamantane com-
pounds. Nevertheless, combinations of adamantanes and novel compounds achieved syn-
ergistic antiviral effects, and the latter synergised with the neuraminidase inhibitor (NAi),
Zanamivir. Thus, site-directed drug combinations show potential to rejuvenate M2 as an
antiviral target whilst reducing the risk of drug resistance.
Author summary
"Swine flu" illustrated that the spread of influenza pandemics in the modern era is rapid,
making antiviral drugs the best way of limiting disease. One proven influenza drug target
is the M2 proton channel, which plays an essential role during virus entry. However, resis-
tance against licensed drugs targeting this protein is now ubiquitous, largely due to an
S31N change in the M2 sequence. Understandably, considerable effort has focused on
developing M2-N31 inhibitors, yet this has been hampered by controversy surrounding
two potential drug binding sites. Here, we show that both sites can in fact be targeted by
new M2-N31 inhibitors, generating synergistic antiviral effects. Developing such drug
combinations should improve patient outcomes and minimise the emergence of future
drug resistance.
Introduction
The 2009 H1N1 “swine ‘flu” outbreak dramatically illustrated the speed at which influenza
pandemics can spread in the modern era due to globalisation. Whilst not as virulent as the
1918 Spanish Influenza, which claimed more than 50 million lives, swine ‘flu caused increased
mortality and morbidity, placing considerable burden upon even advanced health care sys-
tems. The unexpected origin[1–3] of swine ‘flu precluded the rapid deployment of a vaccine,
making antiviral prophylaxis the only means by which to curtail the initial stages of the
pandemic.
Neuraminidase inhibitors (NAi), including Oseltamivir (“Tamiflu”, Roche), Zanamivir
(“Relenza”, GSK) and Peramivir (“Rapivab”, BioCryst), dominate the current influenza antivi-
ral repertoire[4–7]. Teratogenic effects limit use of a polymerase inhibitor licensed in Japan,
Favipiravir[8, 9]. In 2018, the FDA approved the use of Baloxavir marboxil (“Xofluza”, Roche/
Shionogi) for uncomplicated influenza[10], which is a novel class of antiviral targeting cap-
dependent endonuclease in both influenza A and B viruses. Worryingly, NAi resistance is
increasing, with reports of mutant strains in the H7N9 highly pathogenic avian influenza
(HPAI) epidemic in South East Asia[11–18]. Baloxavir marboxil resistance also occurs at a
high rate (~10% of patients) [19] and Favipiravir selects resistance in pandemic H1N1 influ-
enza cell culture[20].
Another class of influenza antiviral, the adamantane M2 proton channel inhibitors (M2i)
amantadine and rimantadine, are now clinically obsolete due to widespread resistance[21, 22].
This is due to a near-ubiquitous S31N polymorphism within M2 (other rarer variants also
occur) generating resistance at little or no associated fitness cost to the virus. Targeting riman-
tadine resistant M2 has been a long-standing priority yet progress targeting M2-N31 is limited
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compared to other minor variants[23–31]. The majority of studies have focused upon adaman-
tane derivatives with various chemical groups linked via the primary amine.
All influenza A strains require virion-associated M2 channels to mediate core protonation
during endocytosis, promoting the uncoating of vRNPs following membrane fusion[32–34].
In addition, strains with a polybasic furin-cleavable haemagglutinin (HA) require M2 to pre-
vent acidification of secretory vesicles to maintain glycoproteins in their pre-fusogenic state
[35–41]. Mature M2 is a 96 aa type III membrane protein that forms tetrameric channels
within membranes[42–45]. Acidic pH promotes M2 channel activity by both enhancing tetra-
mer formation and the subsequent protonation of conserved His37 sensor residues within the
channel lumen[42, 46–49]. This causes conformational shifts in adjacent Trp41 “gates” via a
mechanism that remains debated[50–59]. More than twenty M2 atomic structures exist on the
PDB, although none feature full-length protein. Instead, minimal “trans-membrane” (TM) or
C-terminally extended “conductance domain” (CD) peptides have been investigated as these
regions recapitulate channel function, although the CD region possesses enhanced biological
activity[60]. Interestingly, drug-bound TM and CD structures differ with respect to adaman-
tane binding[61, 62]; TM channels harbour a single lumenal amantadine molecule, whereas
CD structures bind four rimantadine molecules at membrane-exposed peripheral sites, corre-
sponding to the region largely absent from TM peptides. Uncertainty regarding amantadine/
rimantadine binding remains, hampered by the poor chemical probe qualities of adamantanes
and a lack of confirmatory functional studies comparing TM and CD peptides[63–73].
In the present study, we show that CD and TM peptides can be targeted by chemically-dis-
tinct small molecule inhibitors, suggesting that either both M2 binding sites, or potentially
altered M2 conformations, are viable antiviral targets. Critically, this enables synergistic
M2-targeted combination therapy. In silico high throughput screening enriched for novel
compounds with predicted preference for one or other site, validated by the first comparative
TM/CD peptide screen for M2-N31 channel activity. Several hits identified in vitro show anti-
viral activity versus pandemic H1N1 influenza A virus in the laboratory setting, comprising
both modified adamantanes as well as unique scaffolds. Whilst a previously reported adaman-
tane M2-N31 inhibitor rapidly selected resistance in culture, this did not occur for newly
derived compounds. Excitingly, pairs of M2-N31 inhibitors achieved synergy, as did combin-
ing novel scaffolds with the NAi, Zanamivir. Together, these observations provide a firm basis
for rejuvenating M2-N31 as a viable target for much needed drug combinations, which should
help combat the emergence of antiviral resistance.
Results
Robust identification of specific M2-N31 inhibitors in vitro
We adapted an indirect liposome dye release assay for viroporin activity[74–78] for M2 CD
region peptides derived from Influenza A/England/195/2009 (Eng195), a prototypical first
wave virus from the 2009 H1N1 pandemic. In addition to the wild type Eng195 M2 harbouring
N31, we included a mutated S31 peptide to allow validation with rimantadine (Fig 1A). Both
peptides induced equivalent dose-dependent release of carboxyfluorescein (CF) from lipo-
somes, and acidic pH increased M2 activity (S1A and S1B Fig). Critically, rimantadine only
blocked activity of Eng195 M2-S31 peptides, confirming the ability of the assay to discriminate
between susceptible and resistant M2 variants.
Modified adamantane compounds have been shown to inhibit M2-N31 activity[24, 26, 30,
31, 79]. Thus, to validate the assay we tested Eng195 peptides versus a small collection of simi-
lar prototypic molecules that included inhibitors of rimantadine-resistant hepatitis C virus
(HCV) p7[80]. Encouragingly, from nine compounds tested, three modified adamantanes
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inhibited both M2-N31 and M2-S31 peptides (compounds D, H and J, Fig 1B). A further two
adamantanes showed no activity (E, G), and another amiloride-related compound (L) was
similarly inactive (Fig 1B). Interestingly, two amiloride-like molecules (B, K) showed activity
versus M2-S31 but not N31, reminiscent of rimantadine. Lastly, the alkylated imino-sugar
Fig 1. Identification of M2-N31 targeted compounds from prototypic viroporin inhibitor classes. A. Sequences of Eng195 M2 peptides (amino
acids 18–60, corresponding to the “conductance domain” (CD)) used in study, comprising wild type (top) and N31S mutant (bottom). B. M2-N31/
S31 containing Eng195 peptides were assessed for channel forming activity in DOPA/DOPC(DOPE) liposomes containing self-quenching
concentrations of carboxyfluorescein. Activity relative to liposome-only, solvent and untreated M2 peptide controls (100%). At least two biological
repeats were carried out, each with duplicate/triplicate technical repeats of each condition (����� p�0.00001, paired student t-test). C. Cell culture
antiviral effect of rimantadine and adamantane compound D upon Eng195 in a plaque reduction assay. Results are representative of three biological
repeats, each containing two technical repeats (� p�0.05, paired student t-test).
https://doi.org/10.1371/journal.ppat.1008716.g001
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NNDNJ also blocked the activity of both M2 peptides, yet this compound disrupted oligomeri-
sation, as previously shown for HCV p7[80] (Fig 1A and S1C Fig). D, H, J and NNDNJ dis-
played antiviral effects in Eng195 culture (Fig 1C and S2 Fig), establishing the dye release assay
as a robust means of screening for M2-N31 specific inhibitors with genuine antiviral effects.
Ambiguous predicted binding modes for prototypic M2-N31 inhibitors
To gauge how novel M2-N31 inhibitors might bind the channel complex, we generated struc-
tural homology models for Eng195 M2-N31 and S31 based upon the PDB: 2LRF CD structure
from the Chou laboratory[61] (Fig 2A and 2C). This template includes both potential rimanta-
dine binding sites. As noted previously, N31 caused splaying of the trans-membrane domain
(TMD) compared with the more lumenally oriented S31, yet the structure also differed
throughout the helical bundle, consistent with a reported destabilising effect for N31[72] (Fig
2A and 2C). Surprisingly, docking of both rimantadine and novel inhibitors led to distinct
binding poses at the lumenal and peripheral sites for N31 and S31 models. For the wild type
Eng195 M2-N31 model, predicted binding at the peripheral site (defined by D44, R45 and
F48) consistently involved H-bonding to D44, whereas the orientation of inhibitors altered in
S31 models (Fig 2A, 2B and 2D, and S1 Table). Similarly, M2-N31 lumenal interactions
occurred near to the N-terminal neck of the bundle near N31 and V27 (Fig 2A, 2B and 2D,
and S1 Table), whilst binding within M2-S31 models resembled previous structures, occurring
further inside the TMD just above H37. Such N/S31 dependent “flipping” within the channel
lumen has been observed previously[30]. Based upon these observations, we reasoned that
such promiscuous pleotropic binding may result from the chemical properties of adamantane
derivatives, and that molecules with improved molecular fit may exhibit less ambiguous pre-
dicted binding modes. However, it would also be necessary to validate site preferences in vitro
to generate meaningful structure-activity relationships (SAR) for improved M2-N31
inhibitors.
Determination of M2-N31 inhibitor binding preference in vitro
TM peptides lack the majority of the C-terminal extension present within CD peptides that
contains the proposed peripheral binding site. Thus, we hypothesised that lumenally targeted
compounds would inhibit both TM and CD peptides, whereas those with a peripheral site
preference would show activity only against CD peptides. The dye release assay was therefore
adapted to include Eng195 TM peptides, accounting for their reduced biological activity com-
pared to CD (Fig 3A and S1A Fig).
We first tested a published M2-N31 inhibitor, M2WJ332[81], a modified adamantane with
activity against full-length M2-N31 shown to bind within the lumen of a TM domain NMR
structure (A/Udorn/307/1972 (H3N2) M2-S31N, PDB: 2LY0, Fig 3B). Surprisingly, M2WJ332
blocked the activity of Eng195 M2-N31 CD peptides and had no TM-specific activity either
under standard assay conditions (up to 40 μM) (Fig 3C). Thus, M2WJ332 displayed a strong
functional preference for the peripheral binding site in vitro despite its location within the
2LY0 structure[81]. Accordingly, docking of M2WJ332 within the 2RLF-based Eng195 homol-
ogy model resembled other adamantanes by generating poses within both the lumen and the
peripheral site (Fig 3D and S4A Fig). To confirm this phenotype, M2-N31 peptide electrical
properties were also tested using interface lipid bilayers in the presence/absence of M2WJ332
(Fig 3E and 3F, and S3 Fig). Reassuringly, M2WJ332 had remarkably more potent effects
verses CD, rather than TM peptides, confirming that potential artefacts from dye release assays
were not responsible for erroneous M2WJ332 specificity; moreover, TM peptides remained
susceptible to other inhibitors (see below and S3E Fig). Whilst structural and biophysical
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studies have previously compared lumenal and peripheral binding[67, 69], to our knowledge
this represents the first functional evidence supporting the relevance of peripherally targeted
M2 ligands in vitro. Importantly, this suggests that M2-N31 possesses two potential binding
sites to exploit for antiviral discovery.
Screening of novel M2-N31 inhibitors enriched for lumenal or peripheral
site preferences
The next step was to enrich in silico screening libraries for compounds predicted to bind pref-
erentially at one or other M2 site, removing as much ambiguity as possible through extensive
attrition of compound characteristics. Using the Eng195 2RLF-based model as a template,
grids corresponding to each site were targeted by an in silico high throughout screen (eHiTS,
SimBioSys Inc.), based upon a random chemical library and a second input ligand pool
derived through evolution of the compound D molecular structure (ROCS, OpenEye Scien-
tific) (Fig 4A). eHITS score ranked the top 1000 hits for each site and docking scores were
cross-validated using a second software package (SPROUT, Keymodule Ltd.). Short-listing of
compounds involved an attrition protocol directed by agreement between the two binding
scores, compound molecular weight, specific binding pose and drug-like qualities. Prioritisa-
tion of compounds focused upon site selectivity, rather than merely predicted potency. Details
of resultant compounds are summarised in S2 Table.
Compound screens for activity versus TM and CD peptides at 40 μM yielded multiple hits
(defined as a�30% reduction in channel activity for at least one M2 peptide at 40 μM) corre-
sponding to lumenal and peripheral site preferences. Interestingly, more lumenally targeted
hits presented compared to peripheral, and a third class of compound displayed specificity to
TM rather than CD peptides, e.g. compound P6.4 (S2 Table). A minority of compounds dis-
played functional site preferences contradicting docking predictions, yet rational enrichment
of ligand pools in silico had significantly augmented the number of M2-N31 targeted hits, with
~50% of compounds displaying M2-inhibitory activity in vitro compared with a hit rate of
<1% from a random prospective screen[82].
Lumenally and peripherally targeted M2-N31 inhibitors exert antiviral
effects against Eng195 in culture
We next titrated exemplar compounds from each class to ensure specificity corresponded to
that observed in the 40 μM screen and predicted interactions (Fig 4B and S4B Fig). Interest-
ingly, whilst lumenal compounds (e.g. L1.1) displayed equivalent activity against both TM and
CD peptides, some peripherally targeted ligands (e.g. DP9) also began to exert measurable
effects versus TM peptides at higher concentrations. This included DL7, which despite predic-
tions of lumenal binding, displayed clear preference for CD peptides at lower concentrations
(Fig 4B). We hypothesise that this occurs due to inefficient interactions with the partial periph-
eral binding site present at the C-terminus of TM peptides. Moreover, titrations confirmed the
phenotype of TM-specific ligands (e.g. P6.4) (Fig 4B).
Fig 2. Eng195 homology models based upon PDB: 2RLF conductance domain structure. A. Overlapping structures of original 2RLF structure
(green) and Eng195 (E195) homology model (light/dark grey corresponding to TM and C-terminal extension of CD, respectively). B. Docking of
compound D into lumenal and peripheral binding site within Eng195 model. C. Alteration of Eng195 structure caused by occupation of position 31 by
either serine (gold) or asparagine (pale blue). Left: top-down view showing lumenal orientation of Ser31 versus inter-helical Asn31. Middle and zoom:
side view of helical displacement and location of Ser31 versus Asn31 sidechains. D. Docking of Rimantadine and compound D into lumenal (top) or
peripheral (bottom) binding sites of Eng195 homology model with either Ser31 (gold) or Asn31 (pale blue).
https://doi.org/10.1371/journal.ppat.1008716.g002
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Following cytotoxicity testing in MDCK culture (S5 Fig), hit compounds were screened for
antiviral effects in Eng195 plaque reduction assays at 80 μM (Fig 5A). Lumenally targeted L1.1
was the most potent compound, achieving almost a 3 log10 reduction in virus titre. Other hit
compounds, as well as M2WJ332, achieved a 1–2 log10 reduction. Interestingly, with the excep-
tion of a modest effect for P6.4, none of the compounds showing TM peptide specific prefer-
ences in vitro displayed antiviral effects against Eng195 in culture. The most potent lumenal
(L1.1) and peripheral (DP9) hits, along with M2WJ332 (peripheral) and DL7 (peripheral/
lumenal?), advanced to further studies. With the exception of DP9 (25<IC50<50 μM), short-
listed compounds displayed cell culture IC50 values between 1–2 μM (Fig 5B). Thus, data sup-
ported that rational enrichment targeting both distinct binding sites had successfully yielded
M2-N31 inhibitors with potent antiviral effects.
Evolution of Eng195 in M2-N31 inhibitor chronic culture
It was important to establish whether the low genetic barrier to rimantadine resistance was
also relevant to M2-N31 inhibitors. Serial Eng195 MDCK supernatant passage (Fig 6A) was
conducted with increasing concentrations of M2WJ332, L1.1 and DL7 (DP9 excluded as pre-
cise IC50 not determined). Eng195 replication was monitored by periodic titration and Sanger
sequencing of M2 RNA in supernatants. The only change in the M2 sequence was detected
starting from the first analysis of M2WJ332-selected supernatants (day 5); a U>C change at
position 80 (M2 cDNA sequence) led to a Val27>Ala mutation (GUC>GCC, V27A) (Fig 6B).
This polymorphism enriched over time, becoming the dominant species apparent at day 14
(Fig 6B).
Sequencing of plaque-purified virus from day 5 supernatants confirmed the presence of
V27A within 7/7 M2WJ332-selected plaques, whereas 9/9 L1.1-, and 5/5 rimantadine-selected
plaques retained wild type M2-N31 sequence (Fig 6B). Accordingly, far fewer plaques were
derived from normalised L1.1 supernatants compared to M2WJ332 or rimantadine (S6 Fig),
and these were eliminated by limited titration of the compound. By contrast, M2WJ332-se-
lected supernatants still retained multiple plaques (~30% of DMSO control) at much higher
concentrations (80 μM), likely reflecting the proportion of mutant virus (~30–40%, see below)
within the bulk population. Lastly, virus could only be expanded from L1.1 plaques at�20 μM
inhibitor, with cytopathic effects (CPE) taking at least 48 h to manifest. By contrast, M2WJ332
or rimantadine plaques readily expanded under 80 μM inhibitor, with CPE evident by 24 h.
To investigate further whether V27A was potentially linked to M2WJ332 resistance, the
fold increase in titre was determined under selection (80 μM compound) for passages six and
seven. Eng195 under Rimantadine, Zanamivir (known to rapidly select resistance[83, 84]) and
M2WJ332 achieved similar fold-increases compared to DMSO controls, whereas both L1.1
and DL7 significantly suppressed viral replication leading to much reduced titres compared to
input (Fig 6C). We then introduced an evolutionary bottleneck at passage eight to enrich for
any minor resistant variants present within bulk populations, normalising innoculae to a mul-
tiplicity of infection (MOI) of 0.001. After a further six passages, output titres (passage 14)
Fig 3. Analysis of adamantane M2WJ332 biological activity versus M2-N31. A. Structure, sequence composition and binding site grids within
M2-N31 TM (light grey) and CD (C-terminal extension in dark grey) peptides. B. PDB 2LY0 adapted from Wang et al., PNAS 2009 showing
M2WJ332-bound M2 TM domains from an S31N-mutated H3N2 M2 channel complex (Udorn). C. Activity of M2WJ332 in liposome dye release
assay versus M2-N31 TM and CD peptides. Data representative of multiple biological repeats, each containing two technical repeats (� p�0.05,
paired student t-test). D. Predicted docking poses for M2WJ332 at both lumenal and peripheral binding sites upon the Eng195 2RLF-based
channel complex homology model, generated using e-Hits (see also S4A Fig for predicted interactions). E. Inhibition of M2-N31 CD peptide
channels using M2WJ332 within interface lipid bilayers. Results from three independent experiments. Error bars represent standard error of the
mean with p values determined using the student T-test (� p�0.05, �� p�0.01). F. As for E using M2-N31 TM peptides.
https://doi.org/10.1371/journal.ppat.1008716.g003
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again revealed a significant reduction in L1.1 selected Eng195 titre, whereas DL7 selected
supernatants had recovered to a similar range as controls (Fig 6D).
Finally, deep sequencing of IAV genomes was performed comparing passage 5 and 14
supernatants to investigate minor M2 variant populations and mutations occurring elsewhere
in the Eng195 genome (Fig 6E). Only M2WJ332 selected virus showed changes in the M2-N31
sequence compared to controls, with V27A increasing from ~40 to ~80% abundance between
the two time points. Additional minor changes also occurred at position 31 (N31S/I), with
another change located outside of the CD region (E70K). Low prevalence changes also
occurred in the HA protein in M2WJ332 selected virus at passage 14, namely K226E, Y454H/S
and N461D. L1.1 selected virus also showed a low prevalence change at HA Y454H, along with
changes in PB2 D161N and M1 P55S. No variation in M2 sequence was evident for DL7
selected virus at passage 5 or 14, making it difficult to understand the mechanism by which
titre had initially been suppressed and then subsequently rebounded. Interestingly, unlike L1.1
and M2WJ332, DL7 selection drove only two non-synonymous changes within the viral
genome, one each at passage 5 and 14, even though the diversity of synonymous changes was
similar across all conditions, including DMSO controls (Table 1, S3 Table). Hence, it appeared
that DL7 was not in fact driving the evolution of viral sequences over multiple passages, consis-
tent with this compound in fact being inactive during prolonged cell culture. Taken together,
V27A was the only relevant polymorphism significantly enriched during chronic culture with
novel M2-N31 inhibitors. This strongly suggests that Eng195 M2-A27/N31 confers resistance
to M2WJ332.
Synergistic antiviral effects using M2-N31 targeted inhibitor combinations
M2-N31 specific inhibitors with distinct binding properties provides the opportunity for anti-
viral combinations that could not only improve therapy, but also reduce the likelihood of resis-
tance. Combinations of M2WJ332, DP9, DL7 and L1.1 were titrated in Eng195 MDCK plaque
reduction assays and antiviral effects assessed using MacSynergy software (results corrobo-
rated using “Compusyn”). Remarkably, combinations of M2WJ332 with either L1.1 or DP9
yielded synergistic reductions of viral titre (Fig 7A). M2WJ332 combined with L1.1 showed
increased synergy proportionate to both inhibitor concentrations. However, synergy between
M2WJ332 with DP9 only occurred in the lower M2WJ332 range and increased with DP9 con-
centration. By contrast, combinations involving the DL7 compound resulted in antagonism,
whether combined with a lumenally (L1.1) or peripherally (M2WJ332) targeted partner (Fig
7B); this may relate to the observed lack of antiviral effect in long-term culture (see above).
Lastly, L1.1 also achieved synergistic antiviral effects when combined with the NAi, Zanamivir
(Fig 7C and S7 Fig), supporting that drug combinations between classes should be achievable.
Discussion
This work lays the foundation for future combination therapies targeting rimantadine-resis-
tant influenza A viruses, which could form a vital addition to the current pandemic antiviral
repertoire. We have moved beyond the debate surrounding two potential binding sites within
Fig 4. Selection and characterisation of lumenally or peripherally targeted M2-N31 ligands. A. Schematic of inhibitor assay pipeline: left—in silico compound
selection via vHTS showing respective target grids for lumenal and peripheral binding sites (top-down view of M2-N31 tetramer), middle—validation of binding
versus TM and CD Eng195 peptides, right–inhibition assays in Eng195 MDCK culture (Imagery designed using “Biorender” https://app.biorender.com). B. Titration
of class exemplar compounds versus M2-N31 TM/CD peptides in liposome dye release assays: Lumenally targeted L1.1 showing equivalent activity versus both TM/
CD; peripherally targeted DP9 showing preferential inhibition of CD peptides; DL7 showing preference for CD peptides but with activity versus TM at higher
concentrations; P6.4 showing preference for TM peptides (� p�0.05, �� p�0.01, ��� p�0.001, paired student t-test).
https://doi.org/10.1371/journal.ppat.1008716.g004
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Fig 5. Activity of compounds showing specific M2-N31 activity versus Eng195 in vitro in MDCK plaque reduction assays. A. Compounds present at
80 μM both during infection (MOI of 0.01 pfu/cell) and through a 24 hr incubation in producer cells prior to titration of secreted infectivity. Rimantadine
(80 μM) negative and Zanamivir (20 μM) positive controls were included. Data are representative of at least three biological repeats containing duplicate
technical repeats (� p�0.05, paired student t-test). B. 8-point IC50 calculations across log2 concentration steps (triplicates for each point) for hit compounds
L1.1, DL7 and DP9, alongside M2WJ332 in MDCK plaque reduction assays, shown with corresponding molecular structures.
https://doi.org/10.1371/journal.ppat.1008716.g005
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M2 channel complexes, instead showing that synergistic antiviral therapy is achievable using
compounds designed to target one or other region, which ultimately should reduce the inci-
dence of new resistance mutations. Finally, whilst adamantanes still contribute to the M2-N31
chemical toolbox, we describe multiple distinct scaffolds that should provide a start-point for
the next steps in antiviral drug discovery.
The question of how amantadine and/or rimantadine block the activity of M2 from sensi-
tive influenza strains has been debated since two contrasting atomic structures were published
in 2008[61, 62]. However, these and other ensuing studies generally compared TM with CD
peptides, which is likely to bias where prototypic adamantanes bind. This is due to the C-ter-
minal extension in CD peptides inducing a more compact helical bundle that is less favourable
for lumenal interactions compared with the much broader structure seen for TM peptides,
which also lack the majority of the peripheral binding site[67]. Moreover, it is increasingly
clear that M2 peptides are highly malleable, with variable solubilisation conditions exerting
profound effects upon structural studies[50].
Numerous biophysical and other investigations have attempted to define the principle
amantadine/rimantadine binding site, including comparative NMR- and SPR- based binding
studies[67, 69]; current consensus favours the lumen, but with secondary interactions at the
periphery, although many such studies do not include CD peptides. However, perhaps the
most relevant M2 structure solved for lipid-borne CD peptides (PDB: 2L0J)[85] rarely features
in biophysical or other studies, likely due to the technical difficulties associated with the use of
membrane bilayers compared with membrane-mimetic detergents. Notably, the lipidic 2L0J
membrane bundle is less compact compared with other CD structures, and the orientation of
the C-terminal extension, comprising basic helices that form the core of the peripheral binding
site, differs significantly in 2LOJ compared to the detergent-solubilised template used for the
present study, 2RLF[61, 85]. This may explain why fewer peripherally targeted compounds
were selected compared to the lumen; accordingly, re-docking peripheral compounds into
Fig 6. Evolution of Eng195 in culture with targeted compounds. A. Schematic of serial supernatant passage of Eng195 with increasing inhibitor
concentrations. Underlined Sample IDs (serial passage, “SP”1, 2, 3 etc) were stored at 4 ºC for at least 24 hr prior use. Double underlined were
clarified, snap frozen and then thawed prior to use. Green text indicates that the M2 protein was sequenced (bulk direct sequencing). B. Direct
sequencing of secreted vRNA throughout serial passages of M2WJ332-treated virus showing passage 5 and 14 bulk populations, as well as an example
of plaque purified virus from day 5. Progressive enrichment of V27A is apparent and becomes absolute in the plaque-purified samples. C.
Monitoring of viral suppression during the course of selection. Quantification of SP7 output titres after infection by equivalent doses of SP6
innoculae. D. SP14 titres following imposition of bottleneck at SP8 (� p�0.05, ����� p�0.005. ������� p�0.000005, paired student t-test). E.
Longitudinal quantitative whole genome deep sequencing analysis for virus treated with M2WJ332, L1.1 or DL7. Percentage prevalence of changes
relative to controls are shown for SP5 and SP14. M2WJ332 selects both V27A and other minor variants within M2, yet no such changes occur in L1.1
treated cultures. Other minor variants are selected over the course of the experiment in HA and other ORFs for both compounds.
https://doi.org/10.1371/journal.ppat.1008716.g006
Table 1. Synonymous (syn) and non-synonymous (non-syn/NS) changes in E195 whole genome sequencing over the course of fourteen passages of drug selection.
Virus RNA derived from supernatant passages five and fourteen was purified and sequenced, prior to the evolutionary bottleneck and the final passage, as well as a plaque-
purified sample virus from passage five. Data reflects the number of discrete changes present within the sample rather than their prevalence within the population. Com-
plete list of changes is provided in S3 Table.
Day 5 Day 14
Condition Syn Non-Syn Total Syn Non-Syn Total Total Changes % NS
DMSO 36 3 39 38 2 40 79 6.32911392
M2WJ332 10 3 13 45 12 57 70 21.4285714
M2WJ332 plaque 11 3 14 ND ND 14 21.4285714
L1.1 22 3 25 31 9 40 56 21.4285714
L1.1 plaque 16 3 19 ND ND 19 15.7894737
DL7 29 1 30 32 1 33 63 3.17460317
https://doi.org/10.1371/journal.ppat.1008716.t001
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2LOJ using E-Hits results in altered binding poses and affinity scores (S8 Fig). It would be of
great interest to repeat our in silico enrichment using this template to determine whether the
same or altered hits ensued, potentially with greater numbers of peripherally targeted
compounds.
To our knowledge, the present study is the first to compare TM and CD peptides using an
in vitro functional assay. Our hypothesis assumes that the presence/absence of the C-terminal
extension discriminates peripheral binding, thus the identification of CD peptide-specific hits
may represent direct functional evidence that the peripheral binding site represents a drug-
gable target for M2. However, it is also possible that compound specificity may be affected by
altered conformations adopted by CD and TM peptides within liposomes. The equivalent
effects seen for lumenally targeted compounds suggests that the trans-membrane region is
unlikely to differ between longer and shorter peptides, yet whilst the presence/absence of the
C-terminal region is the most obvious explanation for CD-specific compounds, this is still not
definitive. Interestingly, a third class of compounds was identified, including P6.4, that showed
in vitro preference for TM peptides, suggesting that another region of TM from that targeted
by lumenal binders can adopt a distinct structural conformation compared to CD peptides.
However, with the exception of a mild antiviral effect for P6.4 (Fig 5A and S2 Table), none of
these compounds displayed activity in Eng195 culture making their biological relevance
unclear.
Other M2-N31 targeted studies, such as that describing M2WJ332[81], combine TM-
derived structures with compound efficacy data from full-length protein, thereby presuming
that the two structures are directly related. Nevertheless, discovering that M2WJ332 showed a
functional preference for the peripheral binding site was unexpected. It is conceivable that
M2WJ332 interacts differently with Eng195 M2 compared to the protein in the reported TM
structure (A/Udorn/307/1972 (H3N2) M2-S31N, PDB: 2LY0). Moreover, 2LY0 was solved
using relatively harsh detergent conditions[81, 86], rather than lipid, and in the presence of
millimolar rather than micromolar inhibitor concentrations. Nonetheless, whether or not
Eng195 and Udorn M2 are directly comparable as proteins, the present study serves as prece-
dent for effective influenza A virus inhibitors targeting either the M2-N31 peripheral site, or a
conformation distinct from that favouring lumenal binding, for at least one influenza A virus
strain, raising the tantalising prospect of M2-targeted drug combinations.
To exclude potential artefacts from the use of indirect dye release assays when determining
binding site preferences, we also examined CD and TM peptides in a supported bilayer electro-
physiology assay (S3 Fig). Reassuringly, CD peptides were sensitive to nanomolar concentra-
tions of M2WJ332, whereas TM peptides retained channel activity in the presence of much
higher concentrations; L1.1 still inhibited TM peptides (Figs 3E, 3F and S3E). M2 peptides
exhibited single channel activity in this system, yielding currents in the low pico-Ampere (pA)
range as seen in other bilayer studies using electrochemical gradients based upon potassium
ions [43]. However, these properties differ from behaviour of M2 expressed in mammalian
cells when conducting protons, which are likely to be the biologically relevant substrate, where
channel conductance was estimated to comprise femto-Ampere (fA) currents [87]. Other
virus-encoded ion channels have also been shown to transport multiple ionic species and this
may, or may not relate to biologically relevant behaviour in vitro and what causes these
Fig 7. Antiviral effects of M2-N31 inhibitor combinations versus Eng195 MDCK culture. Class exemplar compounds were used in
combination regimens across matrices of increasing concentrations. Resultant antiviral effects were assessed, and MacSynergy used to
determine potential synergistic/additive/antagonistic effects. A. Top-down views of 3D-relief plots are shown with coloured peaks/troughs
representative of synergistic (i.e.>0) or B. antagonistic (i.e.<0) effects. C. Synergistic MacSynergy plot of M2-N31 inhibitor L1.1 used in
combination with Zanamivir (NAi).
https://doi.org/10.1371/journal.ppat.1008716.g007
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differences in conductance is unclear. Moreover, similar questions arise around using CF as a
proxy measure of M2 activity within screening assays, and this may relate to the relatively high
concentrations of inhibitor required to block channel activity compared to full-length protein
in Xenopus Oocytes, for example. Nevertheless, M2 peptide activity was influenced by acidic
pH, compound specificity was confirmed by rimantadine sensitivity dependent upon the S/
N31 resistance polymorphism, and significant enrichment of biologically active inhibitory
compounds was achieved.
Eng195 chronic culture in the presence of M2WJ332 led to the rapid evolution of a V27A
change within the M2 sequence. Both plaque purification and monitoring the titre of selected
bulk populations supported that this change confers specific resistance. V27A is a known
amantadine resistance mutation[88, 89], albeit less prevalent compared to S31N. Amantadine
binds proximal to H37 in the central portion of the trans-membrane helical bundle[64], mean-
ing that S31N and V27A are too distant for these mutations to affect direct contacts with the
drug, making the mechanism of resistance unclear. However, direct contact with V27 and N31
is predicted for lumenally docked compound D and M2WJ332 in the E195 homology model
(Figs 2D and 3A), and this is seen in the 2LY0 TM structure where M2WJ332 interacts with
the lumen [81]. Thus, an obvious explanation for the mechanism of M2WJ332 resistance
would be the disruption of this interaction and resultant destabilisation of compound binding,
contradicting the functional preference for M2WJ332 identified herein. However, the 2LY0
structure lacks the peripheral binding site and M2WJ332-bound CD peptide structures are not
available; as discussed, both peptides also confer distinct structural bias. A distinct allosteric
mechanism must therefore exist in order for V27A mutations to influence peripheral site inter-
actions with M2WJ332. Interestingly, both S31N and V27A mutations destabilise CD peptide
M2 channel complexes, the effects of which were proposed to disrupt interactions with periph-
erally bound rimantadine[72]. V27 is also proposed to form a secondary gate/constriction at
the neck of the channel lumen[90], and a CD structure containing this mutation had both a
wider lumen as well as an altered conformation in the peripheral binding region [91]. Thus, it
seems that the M2 lumen and peripheral regions are structurally linked, meaning that muta-
tions in one region might be expected to influence the other. In this regard, resistance to a
compound related to M2WJ332 was shown recently to arise via a L46P mutation, i.e. located
within the peripheral binding pocket [23]. Hence, it seems neither possible to reinforce nor
contest in vitro data on M2WJ332 peripheral binding based upon the location of V27A at
present.
Notably, naturally occurring M2-N31/A27 double variant isolates exist, implying a low
genetic barrier in nature as well as in cell culture[92]. Interestingly, other minor M2 variants
selected by M3WJ332 included the revertant N31S, which mediates resistance to another pub-
lished M2-N31 specific adamantane derivative; a more dramatic N31D mutation also medi-
ated resistance to a dual M2-N31/S31 inhibitor[93]. However, changes in M2, including at
N31, did not occur in L1.1-selected Eng195, which forms predicted interactions with N31 but
not V27 due to sitting lower in the lumen interacting with the H37 tetrad (S4 Fig). Accord-
ingly, this compound maintained suppression of Eng195 bulk titre throughout the course of
the experiment. DL7 appeared to behave similarly to L1.1 at early times, but titres recovered
following the introduction of the evolutionary bottleneck at passage eight. A lack of non-syn-
onymous sequence changes relative to controls or other drug treatments makes it unlikely that
the compound was driving evolution of the virus in the same way that both L1.1 and
M2WJ332 did and we conclude that this compound was not exerting an antiviral affect over
the course of the resistance experiments. However, this contradicts the action of the com-
pound versus peptides in vitro as well as in 24 hr plaque reduction assays. We speculate that
DL7, like several other compounds we identified, exerts M2 inhibitory activity in vitro, but not
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in cell culture for an undetermined reason, possibly linked to biological availability. Unlike
other inactive compounds, transient treatment with DL7 may exert a cell-specific effect that
serves to diminish IAV titres. Thus, combined with the antagonistic behaviour of this com-
pound in combination studies, we currently consider DL7 deprioritised for future
development.
Irrespective of whether resistance may or may not arise to new M2-N31 specific com-
pounds, the most clinically important observation from this study is that either lumenal and
peripheral binding sites, or distinct M2 conformations, are viable drug targets that allow com-
binations of inhibitors to be used for therapy. Moreover, synergistic, rather than additive, anti-
viral effects were achieved for two of the four combinations tested. Interestingly, whilst it is
clear how M2WJ332 and L1.1 binding at distinct sites might induce synergy, the combination
of the former with another peripherally targeted compound, DP9, is conceptually more diffi-
cult. Notably, the pattern of synergy differed to the other combination as only occurring in the
presence of lower M2WJ332 concentrations. We surmise that this may relate to the availability
of four separate peripheral binding sites upon M2 complexes, as well as the greater potency of
M2WJ332. L1.1 also displayed synergy when combined with Zanamivir. Hence, whilst the
compounds herein represent the initial stages of hit identification for both binding sites, the
indications are that further development will eventually enable double, triple, or even
expanded therapeutic regimens upon inclusion of other agents. Such strategies are applied to
antiviral treatment for other highly variable RNA viruses and there is growing consensus that
such approaches represent the best way forward for influenza A virus. Furthermore, combina-
tions should combat potential shortcomings for individual agents in terms of lower genetic
barriers to potential resistance. Overall, future exploitation of both druggable sites/conforma-
tions within M2-N31 using specific inhibitors has considerable potential to rejuvenate this
essential ion channel protein as a drug target, providing an important additional resource to
combat emergence of future pandemics.
Materials and Methods
Peptide synthesis and reconstitution
Peptides (Eng195 M2-N31 CD and TM, M2-S31 CD) were purchased from Peptides Interna-
tional, and supplied lyophilised as a TFA salt. Both lyophilised and reconstituted peptides (1
mM in 100% methanol) were stored at -20˚C. For details, please see S1 Data.
H-RCSDSSDPLVIAASIIGILHLILWITDRLFFKCIYRRFKYGLK-NH2 (S31 CD, 18-60aa)
H-RCSDSSDPLVIAANIIGILHLILWITDRLFFKCIYRRFKYGLK-NH2 (N31 CD, 18-60aa)
H-RCSDSSDPLVIAANIIGILHLILWITDRL-NH2 (N31 TM, 18-46aa)
M2 activity and drug inhibition using liposome dye release assays
Unilammellar liposomes containing self-quenching concentrations of carboxyfluorescein were
prepared as described[74]. M2 mediated CF release was assessed by incubating up to 50 nM
peptide with 50 μM liposomes (determined by rhodamine absorbance). 100 μl assays were car-
ried out in black-walled, flat-bottomed black-base 96 well plates (Grenier Bio One) with lipo-
somes alone as a control for baseline fluorescence, liposomes + 5% v/v MeOH a negative
solvent only control and 0.5% v/v Triton TX-100 (Triton) as a maximal positive control used
for gain adjustment, setting a level of 90% fluorescence. CF release measured by increased fluo-
rescence was taken as an indicator of peptide induced membrane permeability. A set of 30 or
63 readings (λex = 485 nm, λem = 520 nm) were made at 43 second (s) intervals using a
FLUOstar Galaxy plate-reader (BMG Labtech). Assays were carried out at RT, with the plate
kept on ice for 2–5 min after gain adjustment and while the peptide +/- compound were
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added. All samples were repeated in duplicate on the plate and each experiment repeated three
times (unless otherwise stated). Baseline readings of liposomes alone were subtracted from
each of the wells when calculating end point results.
For compound inhibition assays, a maximum of 1% v/v DMSO was added to each reaction,
with stock inhibitor concentrations diluted accordingly. Compounds or a DMSO control were
pre-incubated with peptides for 20 min at RT prior to addition to chilled liposome suspen-
sions. Baseline-subtracted end point values were averaged and normalised to the peptide
+ DMSO control. Values were then averaged across replicate experiments and standard errors
calculated. Paired t-tests determined statistical significance between the peptide + DMSO con-
trol and compound treated reactions.
Generation of Eng195 homology models based upon PDB 2RLF (octanol,
bilayer)
Published M2 tetramer structures were downloaded from the website of the Research Colla-
boratory for Structural Bioinformatics (RCSB), protein data bank (PDB) http://www.rcsb.org/
pdb/home/home.do). The solution NMR structure of A/Udorn/307/1972 H3N2 (PDB: 2RLF)
[61] was used as a template for an in silico structural homology model of the E195 M2 conduc-
tance domain (A/England/195/2009). Prime and Maestro (Schro¨dinger) were used for homol-
ogy modelling, with the model minimised in an octanol environment. Later, this homology
model was re-minimised in a lipid membrane environment, using an Optimised Potentials for
Liquid Simulations (OPLS) force field and used for docking of unbiased compound analogues.
A second homology model using PDB 2L0J[85] as a template was made, using the SWISS-MO-
DEL (ExPASy) web server and was minimised in an octanol environment using Maestro.
In silico docking, compound selection and attrition
Two binding regions were defined, the lumen concentrated on pore lining residues at the N-
terminal end of the TM domain (V27, A30, N31, I33 and (G34) and the periphery on lipid fac-
ing residues at the C-terminal of the TM domain (W41, I42, T43, D44, R45 and F48).
Open access small molecules libraries were used for an unbiased molecular binding study,
with eHiTS (SimBioSys Inc.) used to dock compounds onto the two pre-defined binding
regions of the Eng195 homology model. Ranked by eHiTS score the top 1000 hits, at each site,
were manually assessed for their binding pose and drug-like qualities, resulting in seven pre-
dicted lumenal binding compounds L1-L7 and six peripheral binding compounds P1-P6 being
selected for testing.
In addition, a biased screen was carried out utilising a rapid overlay of chemical structure
(ROCS) approach and centred on compound D. ROCS (OpenEye Scientific) software was
used and the top 1000 hits were docked against the homology model using eHiTS. Compound
docking at both sites was validated using SPROUT (Keymodule Ltd.) software. A protocol of
attrition was carried out to select DL and DP compounds, focussing on docking scores, molec-
ular weight and specific interactions with the M2 tetramer. Full details are listed in (Section
3.5.1). Briefly, compounds were selected based on agreement between the two binding scores,
molecular weight and specific interactions with the protein. Analogues of selected compounds
were found via the online tool eMolecules (www.emolecules.com). Selected compounds were
subsequently docked against the 2RLF-based E195 M2 homology model using eHiTS.
Chemicals and molecular probes
M2WJ332 ((3S,5S,7S)-N-{[5-(thiophen-2-yl)-1,2-oxazol-3-yl]methyl}tricycle[3.3.1.1~3,7~]
decan-1-aminium) was purchased from Avistron Chemistry Services. Rimantadine
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hydrochloride ((RS)-1-(1-adamantyl)ethanamine) and zanamivir ((2R,3R,4S)-3-acetamido-4-
(diaminomethylideneamino)-2-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-
6-carboxylic acid) were purchased from Sigma, NN-DNJ from Toronto Biochemicals, all other
compounds were purchased from ChemBridge. All commercially purchased lyophilised com-
pound stocks were tested for purity using Liquid Chromatography Mass Spectrometry. Com-
pounds were resuspended in dimethyl sulfoxide (DMSO) to 10–100 mM, aliquoted, and
stored at –20 0C, or –80 0C for long term storage.
Generation of gel-interface lipid bilayers
Electrical measurements of M2 peptides were performed using an interface bilayer formed
between gel-gel interfaces, as shown in S3A Fig. Briefly, a homemade Teflon holder with two
adjacent, connected wells (diameter 6 mm, and depth 8 mm) containing 150 μL agarose gel
(1% w/v in 1 M KCl, 10 mM HEPES, pH 7.0) in one, and the same volume of buffer (1 M KCl,
10 mM HEPES, pH 7.0) in the other. 60 μL hexadecane & silicon oil (10:1) with 8 mg/ml
DPhPC (1, 2-diphytanoyl-sn-glycero-3-phosphocholine, >99%, SIGMA) was next added into
the holder on top of gel and buffer. A lipid monolayer formed at the oil/gel or oil/water inter-
face within a few minutes. A drop of agarose gel (1% w/v in 1 M KCl, diameter ~ 1 mm) was
attached onto a Ag/AgCl electrode (diameter 0.25 mm) and then immersed into the lipid-oil
solution for at least 15 min. At the same time, another Ag/AgCl electrode was immersed into
the KCl buffer. Following formation of a stable lipid monolayer on the surface of the gel drop-
let, this and the Ag/AgCl electrode were slowly lowered until making contact with the gel in
the well, indicated by increased capacitance. Thus, a lipid bilayer was formed at the gel/gel
interface (S3A Fig, insert). A period of several minutes was required to achieve stable capaci-
tance prior to experimentation.
Electrical measurements of interface lipid bilayers
After the formation of gel-gel interface bilayers, a range of voltages (up to several tens of mVs)
was applied using an Axopatch 200 (Molecule Devices LLC, USA), and the current through
the lipid bilayer was recorded. Resistance of the interface bilayer (calculated from the I-V
curve) was generally 4 GO for an area of ~ 100 x 100 μm2. This was checked by repeating the
measurement three times by breaking-apart and re-forming the gel-gel interface lipid bilayer.
Due to variation in the interface area, resistances were normalised to capacitance, i.e. equiva-
lent to the unit area resistance. Normalised values were used to calculate mean conductance,
enabling comparison between different experiments (Normalised Conductance = (ΔI/ΔV)/
Capacitance).
Formation of M2 ion channels and inhibitor effects
Upon formation of stable interface lipid bilayers with resistance normalised to capacitance,
M2 peptide in 100% MeOH was added to one of the wells containing KCl buffer. The maxi-
mum final concentration of methanol was limited to 5% (15 μL MeOH in 300 μL buffer & gel).
Inhibitor assays were conducted using 200/400 (CD) - 1000 (TM) nM peptide, whereas single
channel recordings utilised 1000 x lower concentration of peptide.
After adding peptides, > 1 hr resting time allowed full diffusion within the buffer and the
gel. Note, the top electrode was placed close to the gel/buffer well boundary. Thus, peptides
were required to diffuse for<1 mm rather than 6 mm, which reduced the time necessary for
equilibration. Conductance of the lipid bilayer was then measured as described above, with sig-
nificant increases caused by the addition of peptide. Inhibitors solubilised in DMSO were
added to the buffer well following the formation of M2 ion channels with a maximum final
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DMSO concentration of 1% v/v. S3 Fig describes typical experiments using M2 peptides and
inhibitors.
Plaque reduction assays for antiviral effects
Madin-Darby Canine Kidney (MDCK, obtained from the American Type Culture Collection
(ATCC)) cells were infected with A/England/195/2009 (E195) influenza A virus. MDCKs were
seeded 5 x105 / well of a 12 well plate 4 h prior to infection. IAV was diluted in SF media to a
multiplicity of infection (MOI) of 0.01 or 0.001 and preincubated with compound diluted in
DMSO for 30 min on ice, prior to a 1 h infection. Virus containing media was then removed
and replaced with SF media with the addition of 1 μgml-1 TPCK trypsin and compound before
incubation of the producer plate at 37˚C, 5% CO2. At 24 hpi the media was removed for titra-
tion. Virus containing supernatants were in SF media and dilutions of 10−1 to 10−4 were then
used to infect fresh monolayers of MDCK for one hour. Media was then removed and a 3:7
mixture of 2% w/v agar (Oxoid Purified Agar) and overlay media (Modified eagles medium
(MEM), 0.3% v/v BSA (fraction V), 2.8 nM L-Glutamine, 0.2% v/v NaHCO2, 14 mM HEPES,
0.001% v/v Dextran, 0.1x Penicillin and 0.1x Streptomycin) containing 2 μgml-1 TPCK trypsin
was added to cells. Inverted plates were then returned to the incubator and incubated at 37˚C,
5% CO2 for 72 hr to allow plaques to form. After removal of the agar, cells were fixed in 2 ml
4% paraformaldehyde in PBS for 1 h, then stained with 1 ml of 1% v/v crystal violet solution
for 5 min. Plaques were then counted and virus titres calculated. Each condition was carried
out in triplicate within an experiment, with average titres and standard deviations calculated.
Paired t-tests were carried out to assess statistical significance between DMSO control treated
virus and other compounds.
To determine the half maximal inhibitory concentration (IC50) of plaque formation, half-
log10 dilutions were made from 80 μM, down to 80 nM, except in the case of Zanamivir where
log10 dilutions were made from 80 μM, down to 80 pM.
Chemical cross-linking of inhibitor treated M2 peptides
Crosslinking of Asn31 (N31) and Ser31(S31) M2 peptides was performed using Lomant’s
reagent (Dithiobis[succinimidyl proprionate (DSP, Pierce)). 5 μg of each M2 peptide was
reconstituted in 300 mM DHPC/20 mM sodium phosphate buffer [pH 7.0] overnight in the
absence or presence of 40 μM Rimantadine or NN-DNJ. Following reconstitution, DSP in
DMSO was added to a final concentration of 75 μM. Reactions were incubated at room tem-
perature for 15 min, prior to quenching with 200 mM Tris buffer pH 7.5. Cross-linked reac-
tions were analysed on a 15% Tris-Glycine/6MUrea/SDS/PAGE gel.
Cell viability and proliferation assays
MDCK cells were seeded at 2.5 x104 / well, into flat-bottomed clear 96 well plates (Corning
Costar) and incubated overnight at 37˚C, 5% CO2. Media was removed and cells were treated
with dilutions of compounds up to 160 μM in cell culture media, with a final concentration of
0.2–0.8% v/v DMSO. Cells were incubated with the compound for 48–72 hr at 37˚C, 5% CO2.
3-(4, 5-dimethyl-2-thiazolyl)-2, 5-diphenyl-2H-tetrazolium bromide (MTT), a tetrazolium
dye, was used as a colourimetric indicator of cellular metabolism. A stock solution (2.5 mgml-
1) used to add 50 μg MTT to each of the wells and incubated at 37 0C, 5% CO2 for 4 h. Media
was then replaced by 75 μl of DMSO and incubated at 37 0C for 5 min prior to reading absor-
bance at 550 nm. Data was normalised to cells treated with the appropriate DMSO control
(0.2–0.8% v/v). Cellular confluency after drug treatment was assessed using the IncuCyte
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ZOOM (Essen Bioscience), with measurements of the percentage of well surface occupied by
cells made under phase.
Combination therapy plaque reduction assays and synergy calculations
Combinations of two M2 targeted compounds, or an M2 targeted compound and the licensed
neuraminidase inhibitor Zanamivir were tested. Combination matrices were set up across a
range from 0, 0.2, 1 and 5 μM, or based upon doses corresponding to multiples of the com-
pound IC50 value, with the 0, 0 combination as DMSO control. Each of the 16 conditions was
run in triplicate within the experiment. Virus titres were normalised to the DMSO control, set
to 100% relative virus titre.
The antiviral effect of combinations of inhibitors were evaluated using two methods: 1)
MacSynergy utilising the Bliss independence model, where values<25 at 95% confidence indi-
cate synergy that is insignificant, 25–50 minor but significant, 50–100 moderate and>100
strong synergy. 2) CompuSyn (ComboSyn, Inc., www.combosyn.com) [94] software, which
uses the Loewe additivity model where combination indexes (CI) indicate synergy (<0.9),
antagonism (>1.1) and additive (0.9–1.1) interactions. Data presented in Fig 7 are from Mac-
Synergy, Compusyn data was comparable and is available upon request.
Selection in culture using M2-specific compounds and plaque purification
of single variants
For serial passage using increasing compound concentrations, MDCK cells were seeded into 6
well plates 4 h before the initial infection with Influenza virus was carried out as described
above at an MOI of 0.001, with 2.5 μM compound. At 24 hpi virus containing media was
removed, 1/10th volume was used to infect freshly seeded MDCK cells, as a blind passage and
the remainder was snap frozen. This process was repeated, each time increasing the concentra-
tion of compound present in the media two-fold, until 80 μM was reached. At selected time
points the titre of viral supernatants was determined via plaque assay. These supernatants
could then be used at MOI 0.001, with fresh 80 μM compound, in subsequent infections.
For plaque purification, MDCK cells were seeded in 12 well plates 4 h before infection.
Virus was diluted 1:250 in SF media containing between 5 and 80 μM compound and used to
infect cells for 1 h, before cells were set under overlay media, containing 2 μg/ml TPCK,
0–80 μM compound and agar. At 72 hpi, agar plugs were picked and placed in 300 μl SF media
for 2 h prior to it being used to infect fresh MCDK cells, in the presence or absence of com-
pound (5–80 μM) for 1 h at 37 0C, 5% CO2. Once infectious supernatant was removed, it was
replaced with SF media + 1 μg/ml TPCK and 0–80 μM compound and plates returned to 37
0C, 5% CO2. Once > 40% CPE was observed, infectious supernatant was clarified, prior to
vRNA extraction.
Extraction, purification and sequencing of virion RNA (vRNA)
vRNA was extracted from clarified supernatants using a QIAamp Viral RNA Mini Kit (QIA-
GEN) according to the manufacturer’s instructions. Resultant eluted vRNA was kept at –20 0C
for short term storage, or transferred to -80 0C for long term storage. vRNA was synthesised
into first strand cDNA using SuperScript III (SSCIII) (Invitrogen) and a Eng195 segment 7
specific forward primer (sequences available upon request). A negative control of vRNA but
no SSCIII was included in each experiment.
cDNA was amplified via polymerase chain reaction (PCR) using the proof reading Phusion
high fidelity (HF) polymerase (Phusion) (New England Biolabs). Reactions were heated to 98
0C for 30 s, followed by 35 cycles of the following steps; denaturation at 98 0C for 10 s,
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annealing at 48 0C for 30 s and extension at 72 0C for 40 s and a final incubation at 72 0C for 7
min. Amplified cDNA was purified using a QIAquick PCR Purification Kit (QIAGEN)
according to the manufacturer’s instructions, with eluted DNA concentrations determined
using a nanodrop spectrophotometer and DNA visualised by Tris-acetate-EDTA buffered aga-
rose gel electrophoresis. Samples were stored at –20 0C.
Direct sequencing of virus-derived cDNA
Standard dsDNA sequencing was conducted using the Mix2Seq kit (Eurofins Genomics), with
forward internal primer Eng195_s7_Fint (5’-GGCTAGCACTACGGC-3’) or reverse primer
Flu_s7_R2 (5’-AGTAGAAACAAGGTAGTTTTTTACTCTAGC-3’).
Next Generation sequencing of total genomic viral RNA
vRNA was reverse transcribed by Superscript III (Invitrogen) and amplified by Platinum Taq
HiFi Polymerase (Thermo Fisher) and influenza specific primers[95] in a 1-step reaction.
Library preparation was performed using a Nextera kit (Illumina). Libraries were sequenced
on an Illumina MiSeq using a v2 kit (300-cycles; Illumina) giving 150-bp paired end reads.
Reads were mapped with BWA v0.7.5 and converted to BAM files using SAMTools (1.1.2).
Variants were called using QuasiBAM, an in-house script at Public Health England.
Supporting information
S1 Fig. Characterisation of liposome carboxyfluorescein (CF) release assay for M2 pep-
tides. A. titration of biological activity for Eng195 M2 CD (N31/S31) and TM peptides. TM
peptides form channels less efficiently compared with CD, thereby requiring 320 nM com-
pared with 40 nM for equivalent biological activity at each experimental condition. B. Biologi-
cal activity of M2 peptides in liposome release assay is responsive to acidic pH. End-point
assays were conducted in alternate pH buffers prior to removal of liposomes by ultracentrifu-
gation and re-buffering of reactions to restore CF fluorescence, as described previously. C. Dis-
ruption of M2 oligomerisation by alkylated imino-sugars. M2-N31 and M2-S31 CD peptides
were incubated with liposomes in the presence of 40 μM rimantadine or NN-DNJ, prior to the
addition of DSP (Lomant’s reagent). Resultant M2 complexes were visualised using SDS-Urea
gel electrophoresis.
(TIF)
S2 Fig. Activity of prototypic compounds showing specific M2-N31 activity versus Eng195
in vitro in MDCK plaque reduction assays. Compounds present at 80 μM both during infec-
tion (MOI of 0.01 pfu/cell) and through a 24 hr incubation in producer cells prior to titration
of secreted infectivity. Rimantadine (80 μM) negative control was included. Data are represen-
tative of three technical repeats (� p�0.05, paired student t-test).
(TIF)
S3 Fig. Interface lipid bilayer measurements of M2 peptide activity in the presence or
absence of inhibitors. A. Organisation of the in-house Teflon holder rig used to create gel-gel
interface bilayers as described in materials and methods. Inset shows orientation and forma-
tion of lipid bilayers. B. Example characterisation of bilayers harbouring M2 peptides showing
the of current values at different voltages (left panel), plotted as a histogram fitted by multiple
Gaussian peaks to determine the mean current values at different voltages (middle), allowing
an I-V curve (right) to be plotted for use in calculating normalised bilayer conductance. C. Sin-
gle channel recordings of M2-N31 CD peptides at voltages of +/- 50 mV. D. Normalised con-
ductance of M2-N31 CD versus TM peptides (2000 nM) taken from three independent
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experiments. Error bars represent standard error of the mean with p values determined using
the student T-test (� p�0.05, �� p�0.01). E. Inhibition of TM peptides (2000 nM) using L1.1
(1333 nM) taken from three independent experiments. Error bars represent standard error of
the mean with p values determined using the student T-test (� p�0.05, �� p�0.01).
(TIF)
S4 Fig. Predicted interactions between novel compounds and Eng195 homology model. A.
Predicted interactions between M2WJ332 and the Eng195 (E195) homology model when
docked into the lumen (left) and the periphery (right). Docking studies conducted using
Glide. B. As for A, but detailing L1.1 (Lumen), DL7 (lumen) and DP9 (periphery).
(TIF)
S5 Fig. Metabolic activity of M2-N31 inhibitor treated cells. Compounds showing signifi-
cant activity versus M2-N31 in vitro were assessed for potential cytotoxic effects. MDCK cells
were incubated with increasing compound concentrations (20–160 μM) for 24 h prior to
assessing metabolic activity via MTT assay. Results are representative of at least two biological
repeats, each containing four technical repeats. Error bars are standard deviations within one
biological repeat. Compounds showing any sign of impaired metabolic effects at 40 μM or
greater were discounted from virological screens.
(TIF)
S6 Fig. Plaque purification and expansion of Eng195 bulk cultures from SP5. Normalised
supernatants were diluted and plated onto naïve cells (triplicates in a 12-well plate) in the pres-
ence of increasing inhibitor concentrations for 1 h, after which media was replaced by media/
soft agar containing the same inhibitor concentrations. Resultant plaques (mean from tripli-
cate wells) were counted, plotted as a function of inhibitor concentration, and fitted to expo-
nential curves in Excel with R2 values as shown.
(TIF)
S7 Fig. Determination of Zanamivir IC50 versus Eng195 in MDCK culture.
(TIF)
S8 Fig. Predicted interactions of L1.1, DP9, DL7 and M2WJ332 with lumenal and periph-
eral binding sites in 2L0J-based Eng195 homology model.
(TIF)
S1 Data. Information regarding commercial peptide synthesis provided by Peptides Inter-
national, including purity assessment.
(PDF)
S1 Table. Predicted interactions of adamantane compounds (rimantadine, compound D)
with 2RLF-based Eng195 M2 homology models.
(DOCX)
S2 Table. Properties of M2-N31 inhibitors in vitro and in Eng195 virus culture.
Table summarising the compounds arising from in silico HTS targeting peripheral and/or
lumenal binding sites. Compounds were screened for activity in liposome dye release at least
twice, with several progressed into toxicity and cell culture studies. Compound names and
Chembridge IDs are shown, along with molecular structures and predicted binding (L:
Lumen; P: Periphery) based upon E-Hits/Sprout programmes. M2 activity in the presence of
compounds (40 μM) is shown for M2-N31/S31 peptides corresponding to the CD or TM
regions of the protein. Observed site preferences (Obs L/P) are based upon relative inhibition
of M2 CD/TM activity, with “?” indicating potential binding to lumen or partial peripheral
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binding site based upon compound titrations; bold text indicates differences from predicted
binding. Several compounds were tested versus Eng195 in culture (80 μM) and the order of
magnitude titre reduction across at least three assays is shown. Finally, IC50 was determined
for four compounds selected for synergy experiments.
(DOCX)
S3 Table. Complete list of mutations observed during NGS analysis of serial drug selection
cultures (passage 5 and 14).
(XLSX)
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